Dermata and Revance enter clinical trial collaboration for Xyngari with Daxxify in hyperhidrosis

Dermata Therapeutics, Inc.

Dermata and Revance will collaborate on a Phase 2a trial of topical Xyngari with Daxxify for moderate-to-severe axillary hyperhidrosis.
Trial expected to enroll ~48 patients across US sites; randomized 1:1:1:1, double-blind, placebo-controlled, 16-week evaluation.
Primary endpoints: ≥50% reduction in gravimetric sweat, absolute change in sweat production, and sweat <50mg.
If successful, parties may explore additional indications; Xyngari is currently in Phase 3 for acne; Daxxify approved for glabellar lines and cervical dystonia.
Potential to be first approved needle-free intradermal delivery of a botulinum toxin product.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.